Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients

Endocrine Journal

Volumn 54, Issue 4, 2007, Pages 593-599

  Akinci, Baris ^a   Comlekci, Abdurrahman ^a   Yener, Serkan ^a   Demir, Tevfik ^a   Ozcan, Mehmet Ali ^a   Bayraktar, Firat ^a   Yesil, Sena ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Coagulation; Hyperthyroidism; Plasminogen activator inhibitor 1; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

ANTIGEN; FIBRIN; LYSINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1 ANTIGEN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; FREE THYROXINE INDEX; HUMAN; HYPERTHYROIDISM; MALE;

ADULT; BLOOD COAGULATION; CARBOXYPEPTIDASE U; FEMALE; HUMANS; HYPERTHYROIDISM; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSIS; THYROID HORMONES;

EID: 34548688395     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-176     Document Type: Article

References (29)

1. Vaughan DE (2005) PAI-1 and atherothrombosis. J Thromb Haemost 3: 1879-1883.
2. Hamsten A, Eriksson P (1995) Fibrinolysis and atherosclerosis. Baillieres Clin Haematol 8: 345-363.
3. Haverkate F (2002) Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. Vascul Pharmacol 39: 109-112.
4. Hofbauer LC, Heufelder AE (1997) Coagulation disorders in thyroid diseases. Eur J Endocrinol 136: 1-7.
5. Presti CF, Hart RG (1989) Thyrotoxicosis, atrial fibrillation, and embolism, revisited. Am Heart J 117: 976-977.
6. Marongiu F, Conti M, Mameli G, et al. (1988) Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment. J Endocrinol Invest 11: 723-725.
7. Rogers JS 2nd, Shane SR, Jencks FS (1982) Factor VIII activity and thyroid function. Ann Intern Med 97: 713-716.
8. Dorr M, Volzke H (2005) Cardiovascular morbidity and mortality in thyroid dysfunction. Minerva Endocrinol 30: 199-216.
9. Li Y, Chen H, Tan J, et al. (1998) Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity. Eur J Clin Invest 28: 1050-1054.
10. Ozcan MA, Comlekci A, Demirkan F, et al. (2003) Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders. Thromb Res 110: 243-247.
11. Panzer S, Haubenstock A, Minar E (1990) Platelets in hyperthyroidism: studies on platelet counts, mean platelet volume, 111-indium-labeled platelet kinetics, and platelet-associated immunoglobulins G and M. J Clin Endocrinol Metab 70: 491-496.
12. Ford HC, Carter JM (1990) Haemostasis in hypothyroidism. Postgrad Med J 66: 280-284.
13. Marongiu F, Conti M, Murtas ML, et al. (1991) Activation of blood coagulation and fibrinolysis in Graves' disease. Horm Metab Res 23: 609-611.
14. Panchenko VM, Salakhidinov Z, Khaikina MB (1979) Fibrinogen degradation products, soluble fibrin and antithrombin III in toxic goiter patients. Probl Endokrinol (Mosk) 25: 11-15.
15. Self T, Weisburst M, Wooten E, et al. (1975) Warfarin-induced hypoprothrombinemia. Potentiation by hyperthyroidism. JAMA 231: 1165-1166.
16. Kellett HA, Sawers JS, Boulton FE, et al. (1986) Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med 58: 43-51.
17. Bajzar L, Manuel R, Nesheim ME (1995) Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 270: 14477-14484.
18. Sakharov DV, Plow EF, Rijken DC (1997) On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 272: 14477-14482.
19. Nesheim M (2003) Thrombin and fibrinolysis. Chest 124: 33S-39S.
20. Erem C, Ersoz HO, Karti SS, et al. (2002) Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest 25: 345-350.
21. Guldiken S, Demir M, Turgut B, et al. (2005) Global fibrinolytic capacity in patients with subclinical hypothyroidism. Endocr J 52: 363-367.
22. Muller B, Tsakiris DA, Roth CB, et al. (2001) Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest 31: 131-137.
23. Gelfand RA, Hutchinson-Williams KA, Bonde AA, et al. (1987) Catabolic effects of thyroid hormone excess: the contribution of adrenergic activity to hypermetabolism and protein breakdown. Metabolism 36: 562-569.
24. Zeerleder S, Schroeder V, Hack CE, et al. (2006) TAFI and PAI-1 levels in human sepsis. Thromb Res 118: 205-212.
25. Zorio E, Castello R, Falco C, et al. (2003) Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 122: 958-965.
26. Aubert H, Frere C, Aillaud MF, et al. (2003) Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 1: 791-797.
27. Juhan-Vague I, Renucci JF, Grimaux M, et al. (2000) Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 20: 2156-2161.
28. Kitagawa N, Yano Y, Gabazza EC, et al. (2006) Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients. Diabetes Res Clin Pract 73: 150-157.
29. Akinci B, Comlekci A, Ali Ozcan M, et al. (2006) Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement. Endocr J 54: 45-52.